{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T10:35:22Z","timestamp":1792924522600,"version":"4.5.0"},"reference-count":40,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T00:00:00Z","timestamp":1741046400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Official Development Assistance (ODA)","award":["971521"],"award-info":[{"award-number":["971521"]}],"id":[{"id":"https:\/\/ror.org\/009twqt47","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Background: Old World orthohantaviruses are the aetiological agent of Haemorrhagic Fever with Renal Syndrome (HFRS) disease. Worldwide, the two most prominent pathogens of HFRS are Seoul orthohantavirus (SEOV) and Hantaan orthohantavirus (HTNV). There is currently no specific treatment nor widely licensed vaccine form hantaviruses. Methods: This study developed a virus-vectored vaccine approach using modified vaccinia Ankara (MVA) incorporating a SEOV-HTNV chimeric nucleoprotein antigen. Results: The vaccine demonstrated the induction of humoral and cellular immunity. In the absence of a disease model, a reduction in the viral load of a susceptible mouse strain with type-I interferon receptor deficiency (A129) was used to ascertain protective effects after challenge with SEOV. Results demonstrated a significant reduction in and\/or clearance of viral RNA in immunised animals. Conclusions: An MVA viral vector vaccine incorporating the nucleoprotein as antigen offers a promising approach for Hantavirus vaccine development.<\/jats:p>","DOI":"10.3390\/vaccines13030270","type":"journal-article","created":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T13:31:31Z","timestamp":1741095091000},"page":"270","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["A Multi-Valent Hantavirus Vaccine Based on Recombinant Modified Vaccinia Ankara Reduces Viral Load in a Mouse Infection Model"],"prefix":"10.3390","volume":"13","author":[{"given":"Marilyn","family":"Aram","sequence":"first","affiliation":[{"name":"UK Health Security Agency (UKHSA), Porton Down, Salisbury SP4 0JG, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Graham","sequence":"additional","affiliation":[{"name":"UK Health Security Agency (UKHSA), Porton Down, Salisbury SP4 0JG, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3632-6163","authenticated-orcid":false,"given":"Emma","family":"Kennedy","sequence":"additional","affiliation":[{"name":"UK Health Security Agency (UKHSA), Porton Down, Salisbury SP4 0JG, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Rayner","sequence":"additional","affiliation":[{"name":"UK Health Security Agency (UKHSA), Porton Down, Salisbury SP4 0JG, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Hewson","sequence":"additional","affiliation":[{"name":"UK Health Security Agency (UKHSA), Porton Down, Salisbury SP4 0JG, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart","family":"Dowall","sequence":"additional","affiliation":[{"name":"UK Health Security Agency (UKHSA), Porton Down, Salisbury SP4 0JG, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,3,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1128\/CMR.00062-09","article-title":"A global perspective on hantavirus ecology, epidemiology, and disease","volume":"23","author":"Jonsson","year":"2010","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_2","first-page":"472","article-title":"Epidemiological progresses of hemorrhagic fever with renal syndrome in China","volume":"112","author":"Song","year":"1999","journal-title":"Chin. Med. J."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1586\/14787210.7.2.205","article-title":"Hantavirus infections in Europe: From virus carriers to a major public-health problem","volume":"7","author":"Heyman","year":"2009","journal-title":"Expert Rev. Anti-Infect. Ther."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.virusres.2011.09.017","article-title":"Hantavirus pulmonary syndrome","volume":"162","author":"Macneil","year":"2011","journal-title":"Virus Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"524","DOI":"10.3390\/v6020524","article-title":"Prevalence of antibodies against hantaviruses in serum and saliva of adults living or working on farms in York-shire, United Kingdom","volume":"6","author":"Jameson","year":"2014","journal-title":"Viruses"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1093\/infdis\/146.5.645","article-title":"Laboratory-acquired infections with Hantaan virus, the etiologic agent of Korean hemorrhagic fever","volume":"146","author":"Lee","year":"1982","journal-title":"J. Infect. Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1093\/infdis\/137.3.298","article-title":"Isolation of the etiologic agent of Korean Hemorrhagic fever","volume":"137","author":"Lee","year":"1978","journal-title":"J. Infect. Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"20344","DOI":"10.2807\/ese.18.01.20344-en","article-title":"The continued emergence of hantaviruses: Isolation of a Seoul virus implicated in human disease, United Kingdom, October 2012","volume":"18","author":"Jameson","year":"2013","journal-title":"Eurosurveillance"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"20415","DOI":"10.2807\/ese.18.09.20415-en","article-title":"Pet rats as a source of hantavirus in England and Wales, 2013","volume":"18","author":"Jameson","year":"2013","journal-title":"Eurosurveillance"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"3115","DOI":"10.1017\/S0950268817001819","article-title":"High prevalence of Seoul hantavirus in a breeding colony of pet rats","volume":"145","author":"Mcelhinney","year":"2017","journal-title":"Epidemiol. Infect."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1097\/01.inf.0000142011.98248.15","article-title":"Three-week incubation period for hantavirus infection","volume":"23","author":"Smith","year":"2004","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1099\/0022-1317-49-7-587","article-title":"Hantaviruses","volume":"49","author":"McCaughey","year":"2000","journal-title":"J. Med. Microbiol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.3201\/eid2412.180229","article-title":"Autochthonous Human Case of Seoul Virus Infection, the Netherlands","volume":"24","author":"Swanink","year":"2018","journal-title":"Emerg. Infect. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Clement, J., LeDuc, J.W., Lloyd, G., Reynes, J.-M., McElhinney, L., Van Ranst, M., and Lee, H.-W. (2019). Wild Rats, Laboratory Rats, Pet Rats: Global Seoul Hantavirus Disease Revisited. Viruses, 11.","DOI":"10.3390\/v11070652"},{"key":"ref_15","first-page":"1969","article-title":"Pet Rats Infect Daughter, Mother with Hantavirus","volume":"318","author":"Rubin","year":"2017","journal-title":"JAMA"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"685","DOI":"10.4161\/hv.7.6.15197","article-title":"Human pathogenic hantaviruses and prevention of infection","volume":"7","author":"Klempa","year":"2011","journal-title":"Hum. Vaccines"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"20521","DOI":"10.2807\/1560-7917.ES2013.18.7.20521","article-title":"Pet rat harbouring Seoul hantavirus in Sweden, June 2013","volume":"18","author":"Lundkvist","year":"2013","journal-title":"Eurosurveillance"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1017\/S0950268817001480","article-title":"A seroprevalence study to determine the frequency of hantavirus infection in people exposed to wild and pet fancy rats in England","volume":"145","author":"Duggan","year":"2017","journal-title":"Epidemiol. Infect."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"19961","DOI":"10.2807\/ese.16.36.19961-en","article-title":"A five-year perspective on the situation of haemorrhagic fever with renal syndrome and status of the hantavirus reservoirs in Europe, 2005\u20132010","volume":"16","author":"Heyman","year":"2011","journal-title":"Eurosurveillance"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1016\/j.vaccine.2016.01.031","article-title":"Long-term immunogenicity and safety of inactivated Hantaan virus vaccine (Hantavax) in healthy adults","volume":"34","author":"Song","year":"2016","journal-title":"Vaccine"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3961\/jpmph.19.018","article-title":"Introduction of Vaccinomics to Develop Personalized Vaccines in Light of Changes in the Usage of Hantaan Virus Vaccine (Hantavax(R)) in Korea","volume":"52","author":"Bae","year":"2019","journal-title":"J. Prev. Med. Public. Health"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1099\/0022-1317-79-5-1159","article-title":"Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodu-latory proteins: Implications for use as a human vaccine","volume":"79","author":"Blanchard","year":"1998","journal-title":"J. Gen. Virol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1099\/0022-1317-72-5-1031","article-title":"Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence","volume":"72","author":"Meyer","year":"1991","journal-title":"J. Gen. Virol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/S1473-3099(14)70963-6","article-title":"Safety and immunogenicity of a modified-vaccinia-virus-Ankara-based influenza A H5N1 vaccine: A ran-domised, double-blind phase 1\/2a clinical trial","volume":"14","author":"Kreijtz","year":"2014","journal-title":"Lancet Infect. Dis."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"6671","DOI":"10.1016\/j.vaccine.2008.09.016","article-title":"Lessons from IAVI-006, a Phase I clinical trial to evaluate the safety and immunogenicity of the pTHr.HIVA DNA and MVA.HIVA vaccines in a prime-boost strategy to induce HIV-1 specific T-cell responses in healthy volunteers","volume":"26","author":"Mackie","year":"2008","journal-title":"Vaccine"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"5404","DOI":"10.1016\/j.vaccine.2019.07.023","article-title":"A vaccine based on recombinant modified Vaccinia Ankara containing the nucleoprotein from Lassa virus protects against disease progression in a guinea pig model","volume":"37","author":"Kennedy","year":"2019","journal-title":"Vaccine"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Buttigieg, K.R., Dowall, S.D., Findlay-Wilson, S., Miloszewska, A., Rayner, E., Hewson, R., and Carroll, M.W. (2014). A novel vaccine against Crimean-Congo Haemorrhagic Fever protects 100% of animals against lethal chal-lenge in a mouse model. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0091516"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"12102","DOI":"10.1128\/JVI.01190-07","article-title":"Modified vaccinia virus Ankara induces Toll-like receptor-independent type I interferon responses","volume":"81","author":"Waibler","year":"2007","journal-title":"J. Virol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"5301","DOI":"10.1128\/JVI.73.7.5301-5308.1999","article-title":"Human Memory Cytotoxic T-Lymphocyte (CTL) Responses to Hantaan Virus Infection: Identification of Virus-Specific and Cross-Reactive CD8+ CTL Epitopes on Nucleocapsid Protein","volume":"73","author":"Schmaljohn","year":"1999","journal-title":"J. Virol."},{"key":"ref_30","first-page":"537","article-title":"Analysis of immune responses against nucleocapsid protein of the Hantaan virus elicited by virus infection or DNA vaccination","volume":"43","author":"Woo","year":"2005","journal-title":"J. Microbiol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"3162","DOI":"10.1128\/jvi.64.7.3162-3170.1990","article-title":"Antigenic subunits of Hantaan virus expressed by baculovirus and vaccinia virus recombinants","volume":"64","author":"Schmaljohn","year":"1990","journal-title":"J. Virol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.2741\/4004","article-title":"Immunogenic epitopes of Hantaviruses\u2019 N protein are restricted to conserved regions","volume":"17","author":"Rigo","year":"2012","journal-title":"Front. Biosci."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1016\/j.celrep.2016.02.005","article-title":"Structure of the Hantavirus Nucleoprotein Provides Insights into the Mechanism of RNA Encapsidation","volume":"14","author":"Olal","year":"2016","journal-title":"Cell Rep."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1099\/jgv.0.001470","article-title":"Hantavirus infection in type I interferon receptor-deficient (A129) mice","volume":"101","author":"Dowall","year":"2020","journal-title":"J. Gen. Virol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1373\/clinchem.2007.093245","article-title":"Detection and typing of human pathogenic hantaviruses by real-time reverse transcription-PCR and pyrose-quencing","volume":"53","author":"Kramski","year":"2007","journal-title":"Clin. Chem."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"5.13.1","DOI":"10.1002\/cpps.33","article-title":"Generation of Recombinant Vaccinia Viruses","volume":"89","author":"Wyatt","year":"2017","journal-title":"Curr. Protoc. Protein Sci."},{"key":"ref_37","first-page":"5.12.1","article-title":"Preparation of cell cultures and vaccinia virus stocks","volume":"13","author":"Earl","year":"2001","journal-title":"Curr. Protoc. Mol. Biol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/1469-0691.12259","article-title":"Viral load and humoral immune response in association with disease severity in Puumala hantavirus-infected patients\u2014Implications for treatment","volume":"20","author":"Pettersson","year":"2014","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"166","DOI":"10.3201\/eid1201.050930","article-title":"Neutralizing antibodies in survivors of Sin Nombre and Andes hantavirus infection","volume":"12","author":"Valdivieso","year":"2006","journal-title":"Emerg. Infect. Dis."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1023\/A:1007983306341","article-title":"A major antigenic domain of hantaviruses is located on the aminoproximal site of the viral nucleocapsid protein","volume":"14","author":"Darai","year":"1997","journal-title":"Virus Genes"}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/13\/3\/270\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:47:08Z","timestamp":1760028428000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/13\/3\/270"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,4]]},"references-count":40,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["vaccines13030270"],"URL":"https:\/\/doi.org\/10.3390\/vaccines13030270","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,4]]}}}